The global enteric softgel capsules market size reached US$ 2.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2028, exhibiting a growth rate (CAGR) of 4.15% during 2023-2028.
Enteric softgel capsules have gelatin-based shell coating with semi-solid and liquid medication inside. They are resistant to digestive juices and consequently pass through the stomach unaffected and dissolve in the intestinal tract. They provide several advantages, such as bioavailability, easy usability, and improved adequacy levels. Besides this, they minimize poor aftertaste, optimize dosage efficiency, help treat indigestion, and prevent gastric irritation and reflux. Presently, the increasing awareness among individuals about the benefits of consuming preventive medicines is catalyzing the demand for enteric softgel capsules worldwide.
Enteric Softgel Capsules Market Trends:
The growing global geriatric population, along with the rising prevalence of chronic medical disorders and nutrient-deficient diseases, represents one of the key factors positively influencing the market. In addition, the rising health awareness among individuals and the growing acceptance of nutritional and dietary supplements are catalyzing the demand for enteric softgel capsules across the globe. Besides this, significant growth in the pharmaceutical industry and the expanding applications of the product to enclose omega-3 oils and other gel-based supplements are offering a favorable market outlook. Additionally, product innovations like the introduction of non-gelatin-based enteric softgel capsules are strengthening the growth of the market. In addition, leading players are focusing on manufacturing novel variants by using starch and other organic, plant-based sources to meet the requirements of vegan consumers. Furthermore, the growing expansion of pharmacies and the proliferation of online pharmacies through e-commerce retail channels are creating a positive outlook for the market. Moreover, increasing investments by leading pharma companies in research and development (R&D) activities to improve the bioavailability of these capsules are expected to propel market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global enteric softgel capsules market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, application and distribution channel.
Breakup by Type:
- Gelatin Capsules
- Non-Gelatin Softgel Capsules
Gelatin capsules currently represent the largest market segment due to the increasing vegan population across the globe.
Breakup by Application:
- Health Supplements
Health supplements hold the majority of the global enteric softgel capsules market share due to the increasing usage of softgel capsules by fitness enthusiasts and rising awareness among individuals about nutraceutical supplements.
Breakup by Distribution Channel:
- Supermarkets and Hypermarkets
- Pharmacy and Drug Stores
- Online Stores
Pharmacy and drug stores presently dominate the market on account of the increasing consumer preference to purchase medicinal products from registered pharmacies or drug stores.
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
North America exhibits a clear dominance in the market as healthcare providers are increasingly investing in research and development (R&D) activities to introduce effective treatment alternatives.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Aenova Group GmbH, BASF SE, Catalent, Inc., Colorcon Inc., Fuji Capsule Co., Ltd., Lonza Group AG, Now Health Group, Inc., ProCaps Group, Super Spectrim and Thermo Fisher Scientific, Inc.
|Base Year of the Analysis
||Type, Application, Distribution Channel, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Aenova Group GmbH, BASF SE, Catalent, Inc., Colorcon Inc., Fuji Capsule Co., Ltd., Lonza Group AG, Now Health Group, Inc., ProCaps Group, Super Spectrim and Thermo Fisher Scientific, Inc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)